Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2007

01.09.2007 | Lab investigation-human/animal tissue

Angiogenesis in primary central nervous system lymphoma (PCNSL)

verfasst von: Hiroaki Takeuchi, Ken Matsuda, Ryuhei Kitai, Kazufumi Sato, Toshihiko Kubota

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Angiogenesis and angiogenic growth factors have a major role in the pathogenesis of malignancies. However, very little is known about the clinical and histopathological relevance of angiogenesis in primary central nervous system lymphoma (PCNSL). We investigated that expression of vascular endothelial growth factor (VEGF) of the lymphoma cells and microvessel density (MVD) were examined in 19 patients with PCNSL. Additionally, the presence of the blood–brain barrier (BBB) was examined using immunohistochemistry and the electron microscopy. MVD was significantly higher in nine cases with VEGF immunoreactivity (VEGF+) than in ten cases with negative immunoreactivity for VEGF (VEGF−) (< 0.001). VEGF expression was significantly associated with a longer survival (P < 0.005). BBB markers were negative in angiogenic vessels of VEGF+. BBB markers were identified in vessels surrounding tumor cells and tight junctions were also preserved in the capillary endothelium surrounding tumor cells in VEGF−. Angiogenesis is associated with VEGF expression and an absent BBB in the vessels of PCNSL. The BBB may be preserved in lesions with lymphoma cell infiltration, especially in VEGF− PCNSL. VEGF may have a prognostic effect in PCNSL.
Literatur
1.
Zurück zum Zitat Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 17(4):314–318PubMed Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 17(4):314–318PubMed
2.
Zurück zum Zitat Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G (1999) Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma. Br J Haematol 106(2):504–509PubMedCrossRef Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G (1999) Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma. Br J Haematol 106(2):504–509PubMedCrossRef
3.
Zurück zum Zitat Bono P, Teerenhovi L, Joensuu H (2003) Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 97(11):2767–2775PubMedCrossRef Bono P, Teerenhovi L, Joensuu H (2003) Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 97(11):2767–2775PubMedCrossRef
4.
Zurück zum Zitat Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leuk Lymphoma 44(12):2089–2093PubMedCrossRef Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leuk Lymphoma 44(12):2089–2093PubMedCrossRef
5.
Zurück zum Zitat Ho CL, Sheu LF, Li CY (2002) Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 10(4):316–321PubMedCrossRef Ho CL, Sheu LF, Li CY (2002) Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 10(4):316–321PubMedCrossRef
6.
Zurück zum Zitat List AF (2001) Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 6(3):24–31PubMedCrossRef List AF (2001) Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 6(3):24–31PubMedCrossRef
7.
Zurück zum Zitat Paulus W (1999) Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 43:203–208PubMedCrossRef Paulus W (1999) Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 43:203–208PubMedCrossRef
8.
Zurück zum Zitat Ranieri G, Patruno R, Lionetti A, Di Summa A, Mattioli E, Bufo P, Pellecchia A, Ribatti D, Zizzo N (2005) Endothelial area and microvascular density in a canine non-Hodgkin’s lymphoma: an interspecies model of tumor angiogenesis. Leuk Lymphoma 46(11):1639–1643 PubMedCrossRef Ranieri G, Patruno R, Lionetti A, Di Summa A, Mattioli E, Bufo P, Pellecchia A, Ribatti D, Zizzo N (2005) Endothelial area and microvascular density in a canine non-Hodgkin’s lymphoma: an interspecies model of tumor angiogenesis. Leuk Lymphoma 46(11):1639–1643 PubMedCrossRef
9.
Zurück zum Zitat Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56(1):45–53PubMedCrossRef Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56(1):45–53PubMedCrossRef
10.
Zurück zum Zitat Ridell B, Norrby K (2001) Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS 109(1):66–72PubMedCrossRef Ridell B, Norrby K (2001) Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS 109(1):66–72PubMedCrossRef
11.
Zurück zum Zitat Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M (2002) Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol 58(1):53–56PubMedCrossRef Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M (2002) Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol 58(1):53–56PubMedCrossRef
12.
Zurück zum Zitat Salven P, Teerenhovi L, Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood 90(8):3167–3172PubMed Salven P, Teerenhovi L, Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood 90(8):3167–3172PubMed
13.
14.
Zurück zum Zitat Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br J Cancer 79(5):965–970PubMedCrossRef Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br J Cancer 79(5):965–970PubMedCrossRef
Metadaten
Titel
Angiogenesis in primary central nervous system lymphoma (PCNSL)
verfasst von
Hiroaki Takeuchi
Ken Matsuda
Ryuhei Kitai
Kazufumi Sato
Toshihiko Kubota
Publikationsdatum
01.09.2007
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2007
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-007-9363-x

Weitere Artikel der Ausgabe 2/2007

Journal of Neuro-Oncology 2/2007 Zur Ausgabe

Imagers in Neuron-Oncology Clinical-Patient Studies

A case of Lhermitte-Duclos disease presenting high FDG uptake on FDG-PET/CT

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.